Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by SouthernTierTomon Dec 09, 2021 11:14am
130 Views
Post# 34214558

RE:Bear in mind, our Zacks US journey was a "nightmire"

RE:Bear in mind, our Zacks US journey was a "nightmire""their" ...that's better!

We "joined up" around the same time CTSO did.  Two different Chicago offices "initiated coverage"...CTSO bought the BUY, we dcided on the "HOLD" ( it's paid for coverage peeps )

It got worse though...our Zacks rep ended up in jail shortly after he "finished with us"  TOTALLY confused ( aka me$$ed up currency conversions ) and under reported our market cap by 2/3's Oooooops ; - ) ...I hope we got our money back! ...or did it cost us more?

PMX capacity - "perhaps this is sooo indepth" the simplicity

got "lost in the $huffle"?

"Hard to know" .... "Harder to HOLD" ( just like the one we bought from Zacks ; - )  )

Does anyone have an explanation as to why global health care GIANTS failed to recognize the "limitations" of the filter...indeed, a HUGE factor in the phase 3 FAILURE..now oddly turned SUCCESS as 40% OF THE "failure"  takes on a 75% weighting in the phase 3B FDA confirmatory story.

Hmmmm...still wondering why we split the 6.6 mill from Baxter into 108 tiny pieces over 9 years, or why we showed our lowest revenue quarter in years  ( ~240K..special! ) even though 183K  of it came from the "fun size" 108 piece aknewuity?  SAMI has only been FDA approved since 2018, is that "hinge issue" from March 2015 in a San Diego still an i$$ue?

Hard to know..."harder to HOLD"

RE:Re-visiting the phase 3 Euphrates trial.."Post-Hoc ?'s"

The next round of "questioning" will be in regards to the BIG GAP ( largest of ANY phase 3 subgroup) between the PMX abdominal patients and the "SHAM" abdominal patients.  Please, don't misunderstand me, this was PURELY a result of the "random nature of patient assignment" as it pertians to which group they are applied ( PMX or "SHAM" " ).  That said, it is another one of those 800 LB elephants in the room that MUST BE ADDRESSED as it made "meaningful impact" to the phase 3 Euphrates data.  Don't be afraid to "ask questions" we are ALL here as common shareholders to better learn and understand our "loyal commitment" to this story.

First let us see some discussion around this HUGE point before we carry on with meaningless and potentially damaging discussion that appears to be "purposeful" ; - (

If the PMX filter was approved for use in Japan in 1994, and the EAA diagnostic tool invented in 1994 and FDA approved in 2003, how is it that we enrolled / treated patients with EAA levels that the PMX filter could NOT handle ( AKA - levels that overwhelmed the filter )? The parameters of the diagnostic have been in place for over 2 decades ( see 843 patient MEDIC trial ) The filter itself used on over 300K patients as of today and ~ 200K patients at phase 3 commencement.

.28 is normal, .4 to .6 is elelvated and > .6 is HIGH

In the 7th grade I ran a science fair project that called for the transfer of liquid from a closed container into a fish bowl.  I over estimated the capacity of the fish bowl and the liquid spilled all over my principal's trousers and suede shoes.  I "FAILED" the project, BUT the principal told me "not to go away", that my project was "robust" and in the 8th grade I "repeated the project" and won 1st prize in my class.  I simply ensured that my fish bowl had adequate capacity, I REDUCED the size of my closed container.  FYI, that same principal stepped back an additional 1 yard and wore rubber boots during that 8th grade "Do-Over"

Bon appy,
Tom
ps - I had to pay for new trousers and new shoes for the principal...a small price to pay, as my project is now "SOC" or "standard of class" in many middle school fairs

<< Previous
Bullboard Posts
Next >>